Rigel Pharmaceuticals RIGL Valuation Allowances And Reserves Balance
Valuation Allowances And Reserves Balance at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowancesAndReservesBalance.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's valuation allowances and reserves balance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's valuation allowances and reserves balance?
- Rigel Pharmaceuticals (RIGL) reported valuation allowances and reserves balance of $28.08M in Q1 2026.
- How has Rigel Pharmaceuticals's valuation allowances and reserves balance changed year-over-year?
- Rigel Pharmaceuticals's valuation allowances and reserves balance increased by 0.5% year-over-year, from $27.94M to $28.08M.
- What is the long-term trend for Rigel Pharmaceuticals's valuation allowances and reserves balance?
- Over 2 years (2023 to 2025), Rigel Pharmaceuticals's valuation allowances and reserves balance has grown at a 32.9% compound annual growth rate (CAGR), from $15.68M to $27.72M.
- What does valuation allowances and reserves balance mean?
- This represents the cumulative balance of accounting reserves established to adjust the carrying value of assets, such as inventory obsolescence or bad debt provisions. It reflects management's assessment of potential losses or impairments in the asset base. Significant changes in these reserves can indicate shifts in asset quality or changes in the operating environment.